2.59  -0.06 (-2.26%)		10-27 16:00
Open: 2.72 High: 2.72 Volume: 159,459		Pre. Close: 2.65 Low: 2.52 Market Cap: 2(M)

Short term
Mid term
Targets	6-month :	6.3	1-year :	8.51
Resists	First :	5.39	Second :	7.28
Pivot price	2.78
Supports	First :	2.33	Second :	1.94
MAs	MA(5) :	2.64	MA(20) :	2.78
	MA(100) :	7.02	MA(250) :	15.59
MACD	MACD :	-0.7	Signal :	-0.9
%K %D	K(14,3) :	20.3	D(3) :	21.7
RSI	RSI(14): 38.3
52-week	High :	46.52	Low :	0.75

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ BIAF ] has closed above bottom band by 28.5%. Bollinger Bands are 72.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	2.72 - 2.74	2.74 - 2.75
Low:	2.52 - 2.54	2.54 - 2.55
Close:	2.57 - 2.59	2.59 - 2.62

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.

Mon, 20 Oct 2025
bioAffinity Technologies Presents Research Supporting CyPath® Lung Processing Methods at CHEST 2025 - Business Wire

Thu, 16 Oct 2025
Why Did bioAffinity Technologies' Stock Slip In After-Hours Trading After A Big Day Of Gains? - Sahm

Wed, 15 Oct 2025
bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements - Business Wire

Thu, 09 Oct 2025
$1.8M Registered Direct Offering: bioAffinity Closes 720K Shares to Fund CyPath Lung Sales - Stock Titan

Wed, 08 Oct 2025
$1.8M Offering: bioAffinity to Sell 720,000 Shares at $2.50 to Fund CyPath® Lung Sales - Stock Titan

Wed, 08 Oct 2025
BioAffinity Technologies Stock Surges: What’s Next?​ - StocksToTrade

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Shares Out	0 (M)
Shares Float	5 (M)
Held by Insiders	890530 (%)
Held by Institutions	3.9 (%)
Shares Short	111 (K)
Shares Short P.Month	0 (K)

EPS	-9.49e+006
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	-152.2 %
Operating Margin	-198.2 %
Return on Assets (ttm)	-110.3 %
Return on Equity (ttm)	-1 %
Qtrly Rev. Growth	7.68e+006 %
Gross Profit (p.s.)	-20.13
Sales Per Share	342.92
EBITDA (p.s.)	978633
Qtrly Earnings Growth	-17.2 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-8 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	-2.67

Dividend	0
Forward Dividend	192300
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.